BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jung YS, Park CH, Eun CS, Park DI, Han DS. Statin use and the risk of colorectal adenoma: A meta-analysis. J Gastroenterol Hepatol 2016;31:1823-30. [PMID: 27043957 DOI: 10.1111/jgh.13393] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Patel KK, Sehgal VS, Kashfi K. Molecular targets of statins and their potential side effects: Not all the glitter is gold. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174906] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
2 Wilkins T, Soto J, Afon TI, Seehusen DA. Colorectal Cancer. Family Medicine 2022. [DOI: 10.1007/978-3-030-54441-6_183] [Reference Citation Analysis]
3 Zhang Y, Wu K, Chan AT, Meyerhardt JA, Giovannucci EL. Long-Term Statin Use, Total Cholesterol Level, and Risk of Colorectal Cancer: A Prospective Cohort Study. Am J Gastroenterol 2022;117:158-66. [PMID: 34730560 DOI: 10.14309/ajg.0000000000001543] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
4 Liang PS, Shaukat A, Crockett SD. AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review. Clin Gastroenterol Hepatol 2021;19:1327-36. [PMID: 33581359 DOI: 10.1016/j.cgh.2021.02.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
5 Patel KK, Kashfi K. Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs. Biochem Pharmacol 2021;:114654. [PMID: 34129857 DOI: 10.1016/j.bcp.2021.114654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
6 Barbalata CI, Tefas LR, Achim M, Tomuta I, Porfire AS. Statins in risk-reduction and treatment of cancer. World J Clin Oncol 2020; 11(8): 573-588 [PMID: 32879845 DOI: 10.5306/wjco.v11.i8.573] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
7 Wilkins T, Soto J, Afon TI, Seehusen DA. Colorectal Cancer. Family Medicine 2020. [DOI: 10.1007/978-1-4939-0779-3_183-1] [Reference Citation Analysis]
8 Cavicchi M, Tharsis G, Burtin P, Cattan P, Venezia F, Tordjman G, Gillet A, Samama J, Nahon-Uzan K, Karsenti D. Difference in Physician- and Patient-Dependent Factors Contributing to Adenoma Detection Rate and Serrated Polyp Detection Rate. Dig Dis Sci 2019;64:3579-88. [PMID: 31471862 DOI: 10.1007/s10620-019-05808-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
9 Cheung KS, Chen L, Chan EW, Seto WK, Wong ICK, Leung WK. Statins reduce the progression of non-advanced adenomas to colorectal cancer: a postcolonoscopy study in 187 897 patients. Gut 2019;68:1979-85. [PMID: 30808646 DOI: 10.1136/gutjnl-2018-317714] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
10 Kobayashi Y, Banno K, Kunitomi H, Nagai S, Takahashi T, Anko M, Iijima M, Takeda T, Matoba Y, Nakamura K, Tsuji K, Tominaga E, Aoki D. Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach? European Journal of Cancer Prevention 2019;28:562-7. [DOI: 10.1097/cej.0000000000000497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
11 Qu B, Qu H. The Influence of Statins on Risk and Patient Survival in Colorectal Cancer. J Clin Gastroenterol 2019;53:699-701. [PMID: 28697149 DOI: 10.1097/MCG.0000000000000844] [Reference Citation Analysis]
12 Shah SC, Glass J, Giustino G, Hove JRT, Castaneda D, Torres J, Kumar A, Elman J, Ullman TA, Itzkowitz SH. Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease. Gut Liver 2019;13:54-61. [PMID: 30400722 DOI: 10.5009/gnl18178] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
13 Li Y, He X, Ding Y, Chen H, Sun L. Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta-analysis. Cancer Med 2019;8:3305-13. [PMID: 31069997 DOI: 10.1002/cam4.2151] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
14 Kashfi K, Vannini F. Nitric Oxide and Cancer: To Inhibit or To Induce iNOS: That Is the Question? Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders 2019. [DOI: 10.1016/b978-0-12-816545-4.00005-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Chang WL, Jackson C, Riel S, Cooper HS, Devarajan K, Hensley HH, Zhou Y, Vanderveer LA, Nguyen MT, Clapper ML. Differential preventive activity of sulindac and atorvastatin in Apc(+/Min-FCCC)mice with or without colorectal adenomas. Gut 2018;67:1290-8. [PMID: 29122850 DOI: 10.1136/gutjnl-2017-313942] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
16 Kashfi K. The dichotomous role of H2S in cancer cell biology? Déjà vu all over again. Biochem Pharmacol 2018;149:205-23. [PMID: 29397935 DOI: 10.1016/j.bcp.2018.01.042] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
17 Gottschall H, Schmöcker C, Hartmann D, Rohwer N, Rund K, Kutzner L, Nolte F, Ostermann AI, Schebb NH, Weylandt KH. Aspirin alone and combined with a statin suppresses eicosanoid formation in human colon tissue. J Lipid Res 2018;59:864-71. [PMID: 29444936 DOI: 10.1194/jlr.M078725] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
18 Zelenka J, Koncošová M, Ruml T. Targeting of stress response pathways in the prevention and treatment of cancer. Biotechnol Adv 2018;36:583-602. [PMID: 29339119 DOI: 10.1016/j.biotechadv.2018.01.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
19 Rodriguez-Broadbent H, Law PJ, Sud A, Palin K, Tuupanen S, Gylfe A, Hänninen UA, Cajuso T, Tanskanen T, Kondelin J, Kaasinen E, Sarin AP, Ripatti S, Eriksson JG, Rissanen H, Knekt P, Pukkala E, Jousilahti P, Salomaa V, Palotie A, Renkonen-Sinisalo L, Lepistö A, Böhm J, Mecklin JP, Al-Tassan NA, Palles C, Martin L, Barclay E, Farrington SM, Timofeeva MN, Meyer BF, Wakil SM, Campbell H, Smith CG, Idziaszczyk S, Maughan TS, Kaplan R, Kerr R, Kerr D, Passarelli MN, Figueiredo JC, Buchanan DD, Win AK, Hopper JL, Jenkins MA, Lindor NM, Newcomb PA, Gallinger S, Conti D, Schumacher F, Casey G, Aaltonen LA, Cheadle JP, Tomlinson IP, Dunlop MG, Houlston RS. Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. Int J Cancer 2017;140:2701-8. [PMID: 28340513 DOI: 10.1002/ijc.30709] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 9.3] [Reference Citation Analysis]
20 Horibe Y, Adachi S, Ohno T, Goto N, Okuno M, Iwama M, Yamauchi O, Kojima T, Saito K, Ibuka T, Yasuda I, Araki H, Moriwaki H, Shimizu M. Alpha-glucosidase inhibitor use is associated with decreased colorectal neoplasia risk in patients with type 2 diabetes mellitus receiving colonoscopy: a retrospective study. Oncotarget 2017;8:97862-70. [PMID: 29228657 DOI: 10.18632/oncotarget.18416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Kim EH, Park SW, Nam E, Eun CS, Han DS, Park CH. Role of second-look endoscopy and prophylactic hemostasis after gastric endoscopic submucosal dissection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2017;32:756-68. [PMID: 27796052 DOI: 10.1111/jgh.13623] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]